By Daniel Webster, dWeb.News Publisher
| Source: Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021.
The presentation will provide an overview of the Company’s strategy focusing primarily on its oncology drug pipeline which includes QN-247 and RAS-F assets for which Qualigen has already seen encouraging preclinical data.
Qualigen Therapeutics, Inc. Presentation Details are as follows:
Presentation Webcast: http://www.qualigeninc.com/opco21
Presentation Time: Wednesday, September 22, 2021, 4: 35 pm EDT. The webcast link will broadcast the presentation live, and can be viewed for 90 days thereafter.
Virtual Meetings: Registered attendees will have access to one-on-one meetings online. Qualigen Management will be available throughout each day September 20-22, 2021. Register by contacting your Oppenheimer representative. You may also email email@example.com to register.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Qualigen’s aptamer platform, of which QN-247 is the lead candidate, inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells, thus influencing their proliferation, survival and metastasis. QN-247 has shown promise in pre-clinical studies for the treatment of acute myeloid leukemia (AML). Qualigen’s RAS F platform, a group of RAS oncogene proteins-protein interaction inhibitor small molecules, has shown promise in pre-clinical studies for the treatment of acute myeloid leukemia (AML). It is believed that it disrupts pathways that lead to cancer genes. This mechanism of action could be useful in the treatment of approximately 25% of all cancers, including certain types of lung, colorectal and pancreatic cancers. Recent breakthroughs in the field have prompted a lot of interest in the RAS pathway. This was also evident with the clinical approval for the first K-RAS directed drug earlier this year. Qualigen also has an established diagnostics business that manufactures and distributes highly accurate, proprietary rapid blood testing systems to manage prostate cancer. Qualigen’s management is highly experienced in the development, manufacture, marketing, and distribution of medical devices.
For more information on Qualigen Therapeutics Inc., please visit http://www.qualigeninc.com.
This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. These statements relate to the Company’s strategy and prospects for developing therapeutic drug candidates. Actual results or events may vary from what the Company expects. For example, there can be no assurance that the Company will develop any drugs (including QN-247 and RAS-F); that preclinical or clinical development of the Company’s drugs (including QN-247 and RAS-F, and deprioritized infectious-disease programs such as QN-165) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (including Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company’s owned and in-licensed patent applications; that such patents, if any, and the Company’s currently owned and inlicensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s prospective therapeutic products (including QN-247 and RAS-F, and any repositioning of QN-165); or that the Company will be able to maintain or expand market demand and/or market share for the Company’s diagnostic products. If any of these events or trends are not realized or delayed, or if an actual future event occurs that is different from expectations, the stock price may be affected. Additional information concerning these and other risk factors affecting the Company’s business can be found in the Company’s prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which are available at http://www.sec.gov.
The Company disclaims any intention or obligation to make forward-looking statements after the publication of this news release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
For further information: David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 or (866) 692-6847 Toll Free – U.S. & Canada
Investor Awareness, Inc.
For more dWeb.News Business News: https://dweb.news/news-sections/business-news/